XERS 8-K 2026-10-14

Xeris Biopharma Holdings, Inc. (XERS) 8-K dated 2026-10-14 — accession 0001867096-26-000091. This URL is the filing, not the XERS hub.

Xeris Biopharma Holdings, Inc. (XERS) is a biotechnology company listed on US.

Xeris Biopharma Holdings, Inc. filed a 8-K on 2026-10-14. Accession 0001867096-26-000091.

Cached items: 8.01. EDGAR remains the official archive; Lician keeps this accession as its own indexable page so Google can recrawl the form, not a ticker dump.

Latest reported XERS revenue for 2025-12-31 was $291.8M. Net income was $554.0K. Revenue was up 43.7% from 2024-12-31 to 2025-12-31. XERS currently screens at market cap $760.7M.

Not investment advice. The XERS SEC hub lists recent forms. The stock page is the research view.